(NASDAQ: ANTX) An2 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.88%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 70.2%.
An2 Therapeutics's earnings in 2026 is -$34,553,000.On average, 4 Wall Street analysts forecast ANTX's earnings for 2026 to be -$42,798,004, with the lowest ANTX earnings forecast at -$42,355,005, and the highest ANTX earnings forecast at -$42,733,175. On average, 4 Wall Street analysts forecast ANTX's earnings for 2027 to be -$38,573,308, with the lowest ANTX earnings forecast at -$45,531,631, and the highest ANTX earnings forecast at -$30,631,745.
In 2028, ANTX is forecast to generate -$30,491,282 in earnings, with the lowest earnings forecast at -$29,295,545 and the highest earnings forecast at -$31,388,084.